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ABSTRACT
The natural species tropism of hepatitis C virus (HCV) is limited to
humans and higher primates. Due to the limited availability of chimpanzees,
the establishment of a small-animal model for the study of HCV infection has a
high priority. The recent identification of the human cellular receptors that are
essential for HCV entry together with the advances in mouse genome
engineering provides the bases for creating an inbred mouse model of HCV
infection and propagation.
In our study we designed a gene targeting strategy to produce novel
humanized mouse strains expressing human-specific HCV entry receptors.
Human genes for HCV essential entry factors were introduced in the mouse
genome by homologous recombination in murine embryonic stem cells. To
achieve the native expression patterns of their murine orthologues, we adopted
a knock-in approach replacing the murine genes with human coding sequences.
Three novel humanized mouse strains were generated, expressing respectively
human CD81, scavenger receptor class B member 1 and occludin. Molecular
analyses of mice genomic DNA and messenger RNA confirmed the presence
and germ line propagation of the human genes, and their transcription.
The native regulated expression of human-specific HCV entry receptors
can overcome the major block to HCV replication in murine cells. To verify
the virus entry into the cells of our humanized mice, we successfully optimized
isolation and culture of murine primary hepatocytes and HCV pseudotype
particles infection assay. Genetic humanization of mice for species-specific
HCV receptors could allow HCV glycoproteins mediated cell entry and could
be an important tool for in vivo studying of virus-host interactions.
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1. BACKGROUND
1.1 HEPATITIS C
1.1.1 Biology of hepatitis C virus (HCV)
The hepatitis C virus (HCV) is a small, enveloped RNA virus that
causes liver fibrosis, cirrhosis and hepatocellular carcinoma. The liver is its
primary target organ and the hepatocyte is its primary target cell. More than
170 million people (nearly 3% of worldwide population) are currently infected
with HCV. A notable feature of HCV infection is its tendency to become
chronic: ~70% of acute infections become persistent, and chronic cases are
often associated with serious liver disease (Hoofnagle 2002, Alter and Seeff
2000).
The molecular characterization of HCV became possible approximately
twenty years ago with the cloning of the viral genome, which led to its
classification in a separate genus, Hepacivirus, of the Flaviviridae family
(Choo et al. 1989).
HCV circulates in various forms in the serum of an infected host,
including virions bound to lipoproteins, which appear to represent the
infectious fraction, virions bound to immunoglobulins and free virions
(Bradley et al. 1991, Thomssen et al. 1993). HCV virions have not yet been
visualized conclusively by means of electron microscopy, and therefore
information on their tridimensional structure is lacking. By analogy with the
known   structures of closely related flaviviruses and alphaviruses, HCV is
thought to adopt a classical icosahedral scaffold in which its two envelope
glycoproteins, E1 and E2, are anchored to the host cell-derived double-layer
lipid envelope (Ferlenghi et al. 2001, Khun et al. 2002). Underneath the
membrane is the nucleocapsid that is likely composed of multiple copies of the
core protein, forming an internal icosahedral viral coat that encapsidates the
genomic RNA (Penin et al. 2004).
The HCV genome consists of a positive single-stranded RNA of 9.6
kilobases. It encodes a single open reading frame (ORF) that is flanked by 5’
and 3’ untranslated regions (UTRs), including control elements required for
translation and replication (Simmonds et al. 2005) (Fig 1).
The 5’ UTR contains an internal ribosome entry site (IRES) that
facilitates the translation of the capless HCV RNA. The 5’ UTR also contains
essential replication signals for the negative-strand RNA, which serves as the
replicative intermediate (Friebe et al. 2001). The 3’ UTR has a tripartite
structure and is essential for HCV replication. In addition to directing the
synthesis of the negative-strand RNA, the 3’ UTR can also increase HCV
IRES-mediated translation in the proper genomic context (Yi and Lemon
2003).
The UTRs flank an uninterrupted ORF encoding a single polyprotein of
approximately 3000 amino acids, which is co-translationally and post-
translationally processed by cellular and viral proteases to form three structural
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protein (core, E1 and E2), an ion channel protein (p7) and six other non-
structural proteins (NS) (Penin et al. 2004).
The structural proteins are located at the N-terminus and are released
from the polyprotein by host signal peptidases that cleave signal peptides
located between core/E1, E1/E2, E2/p7 and p7/NS2 (Penin et al. 2004). The
cleavage of the signal sequence between core/E1 yields to the immature form
of the core protein, which is further processed by another host peptidase into a
mature protein of approximately 21 kDa. This maturation process promotes the
transport of the core from the endoplasmic reticulum (ER) membrane to the
surface of the lipid droplets, the site of HCV particle assembly. The core’s N-
terminus is highly basic and has been implicated in RNA binding and homo-
oligomerization, both important properties of a nucleocapsid protein (Targett-
Adams et al. 2008). E1 and E2 are envelope glycoproteins on the viral surface
that are responsible for receptor binding and HCV entry into target cells. The
C-terminal transmembrane domains of these proteins direct them to the ER
membrane, the presumed site where HCV capsid particles pick up their
envelopes before leaving the cell. E1 (192 amino acids) and E2 (363 amino
acids) are both heavily glycosylated and form a non-covalent heterodimer
(Brazzoli et al. 2005). Although the correct folding of these two proteins
appears to depend on each other, E2 is the major ligand that binds to CD81 and
SR-BI (scavenger receptor class B type I), two of the several HCV receptors
identified so far (Pileri et al. 1998, Scarselli et al. 2002).
The p7 protein is a hydrophobic peptide of 63 amino acids. Both N- and
C-termini of p7 face the ER lumen, indicating that it contains two TM
domains. HCV p7 oligomerizes on the ER membrane and forms hydrophobic
pores with ion channel activity. Although dispensable for RNA replication, p7
is essential for the production of infectious viruses both in vivo and in vitro,
indicating a potential role of this protein in viral assembly and release (Griffin
et al. 2003).
Down-stream of the structural protein, NS proteins are located in the
order: NS2, NS3, NS4A, NS4B, NS5A, NS5B. They coordinate the
intracellular processes of viral life cycle. Proteolytic processing within the NS
region occurs through the action of two viral enzymes: the NS2 cysteine
protease, which cleaves at the NS2/3 junction, and the NS3-4A serine protease,
cleaving at all downstream sites (Bartenschlager et al. 1994).
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Fig 1 - HCV genes and gene products (Lindenbach and Rice 2005). Panel A: The structure of
the viral genome, including the long ORF encoding structural and nonstructural genes, and 5’
and 3’ UTRs. RdRP, RNA-dependent RNA polymerase. Panel B: The topology of HCV proteins
with respect to a cellular membrane.
Enveloped HCV particles interact with specific surface receptors and
are internalized. Fusion of the viral and cellular membranes, presumably
triggered by the low pH of the endocytic compartment, leads to the release of
the single-stranded RNA genome into the cytoplasm of a newly infected cell.
This genome serves multiple roles within the virus life cycle: firstly as a
messenger RNA (mRNA) for translation of the viral proteins; subsequently as
a template for RNA replication; and finally as a nascent genome packaged
within new virus particles. Virions, presumably, form by budding into the ER
and leave the cell through the secretory pathway (Brett et al. 2005) (Fig 2).
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Fig 2 - HCV life cycle (Lindenbach and Rice 2005). After entry into the cell and uncoating, the
HCV genome plays three main roles: translation, replication and packaging into nascent
virions.
The first step of HCV infection is the attachment of the virus to the host
cell surface, where attachment molecules such as glycosaminoglycans and low-
density lipoprotein receptor (LDL-R) may mediate this initial interaction.
Subsequently, specific binding between viral envelope glycoproteins and entry
receptors induces a receptor-mediated endocytosis and the internalization of
HCV particles through the cell plasma membrane (Koutsoudakis et al. 2006,
Agnello et al.1999).
HCV RNA does not contain a structure similar to the 5’ cap required
for eukaryotic translation; instead it exploits an IRES-based cap-independent
approach for protein synthesis. HCV IRES, located within the 5’ UTR, can
induce conformational changes in the 40S subunit of the ribosome that allow
the formation of the active 80S complex in the absence of a 5’ cap or ATP-
dependent scanning (Wang et al. 1993).
Like in all positive-strand RNA viruses, HCV replication occurs on
intracellular membranes. In fact HCV forms a replication complex (RC) on the
ER membrane that includes the viral genome, NS proteins and cellular cofactor
(Quinkert et al. 2005).
HCV assembly appears to occur on lipid droplets, and the core protein
clearly coats the surface of this organelle. Although the details are still lacking,
1. Background
9
a generalized model of HCV assembly has been proposed. This model suggests
an important role of the very low-density lipoproteins (VLDL) pathway and
NS proteins in the virus particles assembly. A reasonable proposal is that NS
proteins are divided into at least two pools in the infected cells; one participates
in the replication process and is incorporated into the RC, whereas the other is
involved in particle assembly. In addition, it is likely that the association with
lipoproteins and lipids affects the buoyant density of the virions (Quinkert et al.
2005).
1.1.2 In vitro model systems to study HCV infection
Discerning the mechanisms of HCV cell infection has been difficult for
a long time due to the absence of an appropriate animal model and an efficient
in vitro cell culture system supporting the complete HCV life cycle and
enabling the production of infectious virus particles. For unknown reasons,
serum-derived HCV poorly replicates in primary human hepatocytes and
hepatoma cells in vitro. Thus, several surrogate models have been used in
studies of virus entry before the development of an in vitro cell culture system,
allowing the reproduction of all steps of the HCV replication cycle, including
cell entry (Wakita et al 2005).
In the absence of a reliable in vitro model for virus multiplication, a
truncated, soluble form of recombinant E2 glycoprotein (sE2) was used to
search for candidate receptors involved in HCV cell entry. Two major HCV
receptors, the human tetraspanin CD81 and the human scavenger receptor,
were isolated in screening based on sE2 binding. The limitation of this system
was the fact that the viral glycoproteins E1 and E2 form a heterodimer on the
viral envelope and thus isolated E2 may behave differently (Flint et al. 1999).
An important breakthrough in getting access to a system that most
closely mimics entry of authentic HCV cell entry was the development of HCV
pseudotypes. This system is based on the production of retroviral or lentiviral
particles that incorporate unmodified HCV glycoproteins into the lipid
envelope (Bartosch et al, 2003b, Hsu et al, 2003). The production of HCV
pseudotypes is achieved by co-transfection of 293T cells with plasmids
encoding three components: full-length E1 and E2 glycoproteins, retroviral or
lentiviral core and polymerase proteins, and a proviral genome carrying a
marker gene, such as green fluorescent protein or luciferase. These particles are
infectious and show a tropism for human liver cells. Moreover, cell entry of
HCV pseudotypes is neutralized by antibodies directed against the E2 protein
(Bartosch et al, 2003a). The main drawback of this system is that it mimics
only the very early steps of infection:  from particle binding to the liberation of
the capsid.
The development of the first in vitro model reproducing the complete
viral replication cycle and supporting the production of authentic virus particles
that are infectious in vitro and in vivo was an important milestone in the HCV
field. Cell culture-produced HCV (HCVcc) model is based on a particular
genotype 2a virus strain, JFH-1, cloned from the serum of a patient with
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fulminant hepatitis C. Human hepatoma Huh-7 clones transfected with the
JFH-1 genome efficiently replicate the virus and secrete infectious particles
(Lindenbach et al, 2005, Wakita et al, 2005). Although this HCV in vitro
replication model mimics a natural HCV infection, it has some important
limitations: it is restricted to two particular cell lines (Huh-7 and LH86), which
have abnormal lipoprotein metabolism, and essentially to the JFH-1 strain
(Burlone and Budkowska 2009).
1.1.3 Cellular receptors for HCV entry and host specificity
Virus entry is defined as the steps from particle binding to the host cell
up to the release of the viral genome to its replication site within the target cell.
This process relies on specific interactions between virus components, mainly
envelope proteins and several cellular factors. HCV entry is a slow and
complex multistep process involving the presence of several entry factors.
Initial host cell attachment may involve glycosaminoglycans and the LDL-R,
after which the particle appears to interact sequentially with four entry
receptors: the tetraspanin CD81, the scavenger receptor class B member 1 (SR-
BI) and the tight-junction proteins claudin-1 (CLDN-1) and occludin (OCLN)
(Tang and Grisé 2009).
CD81, a member of the tetraspanin protein family, is probably the best-
characterized receptor molecule for HCV entry. It was first identified as a
soluble E2-binding protein (Pileri et al. 1998), and its critical role in HCV
entry has been confirmed in all model systems (Helle and Dubuisson, 2008).
The E2-binding site on CD81 has been mapped to a large extracellular loop of
89 amino acids. Ectopically expressed CD81 is necessary, but not sufficient, to
allow entry of HCV into non-permissive cells, indicating the presence of
additional entry factors (Zhang et al. 2002).
Accumulating evidence supports a critical role for SR-BI in the HCV
entry process: both anti-SR-BI antibodies and RNA interference directed at
SR-BI mRNA could inhibit infection of HCV pseudoparticles and HCVcc
(Dubuisson et al. 2003, Zeisel et al. 2007). Like that of CD81, the expression
level of SR-BI in Huh-7-derived cells lines can regulate cell permissiveness or
HCV infectivity (Zeisel et al. 2007). Because SR-BI interacts with both high-
density lipoproteins and soluble E2, it remains unclear whether the interaction
between SRBI and HCV is direct or mediated by HCV-associated lipoproteins
(Grove et al. 2007).
Getting evidence that even the simultaneous expression of CD81 and
SR-BI on the cell surface of many cell lines was insufficient to support HCV
pseudoparticles entry, Evans and colleagues set out to identify additional entry
cofactors using an expression cloning approach. Their effort successfully
identified CLDN-1, a tight-junction protein, that revealed to be essential for
HCV entry. Interestingly, an interaction between CD81 and CLDN-1 has been
observed, suggesting a co-receptor complex formation (Harris et al. 2008,
Yang et al. 2008).
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CLDN1 has been shown to be essential for HCV infection of human
hepatoma cell lines, even though there is still no evidence that CLDN1 binds
HCV directly. In addition, human cell lines such as HeLa and HepH (CD81-
and SR-BI-positive) remained HCV resistant when overexpressing CLDN1,
suggesting that additional factors were required for successful HCV cell entry
(Evans et al. 2007). Recent studies have provided evidence that OCLN, another
transmembrane component of the tight junctions, plays an important role in
HCV cell entry and initiation of a productive HCV infection (Liu et al. 2009).
Targeting CLDN1 and OCLN by RNA interference demonstrated that
reduction of the expression of both of these molecules inhibited HCV
pseudoparticles and HCVcc cell entry (Liu et al., 2009). Furthermore OCLN
interacts directly with E2 glycoprotein as demonstrated by co-
immunoprecipitation and pulldown assays (Benedicto et al. 2008, Liu et al.
2009).
Of the four entry factors identified so far, CD81 and OCLN determine
the species specificity of HCV entry between mouse and human, as mouse
CLDN-1 and SR-B1 worked similarly as the human counterparts (Ploss et al.
2009).
Very little is known about how these factors co-ordinate to facilitate the
actual viral entry process. A current model predicts a multistep process that
includes attachment and receptor binding, post-binding association with tight-
junction proteins and then internalization by endocytosis, which is followed by
a pH-dependent step that results in the fusion of membranes and the release of
viral RNA into the cytoplasm of the host cells (Fig 3) (Ploss et al. 2009).
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Fig 3 - Current model of HCV entry into host cells (Ploss et al. 2009). In the blood, virions are
complexed to lipoproteins. These complexes are thought to interact with a number of
hepatocyte cell surface proteins, including LDL-R, glycosaminoglycans, SR-BI, CD81, and, most
likely at later stages, the tight junction proteins CLDN1 and OCLN.  CD81 and OCLN represent
the minimal human-specific entry factors. Although both mouse and human variants of SR-BI
and CLDN1 can mediate HCV entry in the cell culture model system, human variants of CD81
and OCLN are mandatory for HCV entry. After receptor engagement, the virion is internalized
via clathrin-dependent endocytosis. The early endosome is then acidified, and this leads to
fusion of the viral envelope with the endosomal membrane and release of the viral genome
into the cytoplasm.
1.1.4 Development of in vivo small models for HCV infection studies
The natural species tropism of HCV is limited to humans and
chimpanzees. Due to the limited availability of chimpanzees, high costs and
ethical aspects, the establishment of a small-animal model for the study of
HCV infection has a high priority. Rodents are certainly the most appropriate
model for all biological studies. Their short gestation period (around 20 days
for mice and rats), their small size and their low cost are particularly
advantageous. A mouse model with exogenously introduced HCV
susceptibility traits could facilitate in vivo studies of HCV infection. Two
alternative approaches can be proposed to achieve this: the virus could be
adapted to infect non-human cells, or rodent tissues could be humanized
(Fig 4). The latter might be achieved either by xenotransplantation of human
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tissues, or by genetic manipulation to express or ablate key genes (Ploss and
Rice 2009).
To produce a virus that efficiently enters mouse cells, HCV
glycoproteins could be adapted in vitro to use mouse orthologous of human
essential entry factors. Although mouse SR-BI and CLDN1 can mediate effi-
cient HCV pseudoparticles uptake, CD81 and OCLN must be of human origin
to render mouse cells permissive to HCV infection (Ploss et al. 2009). The
HCV glycoproteins have remarkable plasticity, as shown by the continuous
escape of the virus from neutralizing antibodies along chronic infection (von
Hahnt et al. 2007). Three mutations in E1 and E2 were selected after the serial
passage of HCV on human cells that express only mouse CD81 and these
changes enhanced mouse CD81-dependent uptake to levels comparable with
infection using the human orthologue CD81 (Bitzegeio and Pietschmann,
2008). A similar approach could be envisioned for the adaptation of HCV to
entry through mouse OCLN. However the adaptive mutations required for the
use of mouse CD81 might not be compatible with the changes needed to allow
the engagement of mouse OCLN.
Adapting the murine environment to support the replication of HCV is
an alternative approach that has already met with success. Chimeric mice that
harbor HCV-permissive tissue can be obtained by transplanting human
hepatocytes into mouse recipients with liver injury and severe
immunodeficiency (Meuleman and Leroux-Roels 2008). The most commonly
used recipient strain is a transgenic mouse overexpressing urokinase-type
plasminogen activator. This enzyme overexpression is hepatotoxic and results
in homozygous mice with severe liver damage (Heckel et al. 1990), which can
be rescued by transplanting non-transgenic (human) hepatocytes. These
chimeric-liver mice are susceptible to human hepatotropic pathogens, including
HCV. The inoculation of HCVcc or sera from HCV-positive patients into these
mice leads to a rapid increase in viraemia (Lindenbach et al. 2006).
Unfortunately, chimeric-liver mice can be produced only in small numbers, and
their use is limited by logistical constraints and substantial variability.
Pathogenesis and immunity studies are also limited in liver chimeric mice, as
the animals lack a functional immune system.
An inbred mouse model with inheritable susceptibility to HCV would
overcome the technical difficulties of the xenotransplantation model. After the
discovery of CD81 as an essential HCV entry factor (Pileri et al. 1998), trans-
genic mice expressing the human protein in a wide variety of tissues were
produced (Masciopinto et al. 2002). However, human CD81-transgenic mice
were resistant to HCV infection. This led to the conclusion that the expression
of human CD81 alone is insufficient to confer susceptibility to HCV infection
in mice. Enthusiasm for creating an inbred mouse model for HCV has recently
been rekindled by the identification of OCLN as the second human factor that
is essential to overcome the cross-species barrier at the level of entry (Ploss
et al. 2009). However, to accurately reproduce the complex process of HCV
entry in vivo, it will be important to achieve native expression patterns of the
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human HCV entry factor orthologues. Advances in mouse genetics, including
bacterial artificial chromosome transgenics and knock-in approaches, will
undoubtedly be crucial in achieving this. Such a model would allow HCV-
glycoprotein-mediated entry in an inbred mouse strain, and would be an
invaluable tool for analyzing HCV entry in vivo and for preclinical testing of
new intervention strategies.
Fig 4 - Strategies to create mouse models for HCV (Ploss and Rice 2009). Viral adaptation (I),
genetic host humanization (II) and humanization by xenotransplantation (III) are the proposed
approaches to create mouse models for HCV infection.
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1.2 GENETICALLY ENGINEERED MICE AS MODEL SYSTEM FOR
BIOMEDICAL RESEARCH
Experimental models are required to understand human biology in both
its normal and pathological aspects. Clinical studies certainly have many
intrinsic limits: inducing pathology is unacceptable, patients tissue samples are
not always available, the embryonic life is not very accessible. In vitro and cell
culture systems are a very important tool, but they do not allow us to study
physiological systems in their entirety.
The mouse is an excellent experimental model for defining human biology
because of its anatomic, physiologic, and genetic similarity to humans. The
recent genomic sequencing efforts suggest that we share 99% of our genes with
the mouse. Furthermore the mouse is small, has a short gestation period
(around 20 days), can be inbred and maintained cost-effectively. The mouse is
also a popular model because its genome can be readily manipulated by
molecular biology techniques. For example, mouse geneticists can eliminate or
overexpress genes in the whole animal or in a specific tissue, introduce large
regions of DNA into the genome, and engineer whole chromosomes.
Furthermore, inbred strains of mice also provide the opportunity to study a
disease trait in a defined genetic background. In the last few years, a number of
significant technological advances have dramatically increased our ability to
create mouse models of human diseases. These technological advances have
been greatly aided thanks to the of mouse genome sequencing and the
subsequent mouse genomic resources that have been developed (Palgen 2003,
van der Weiden et al. 2002).
Viral or mammalian DNA injected into mouse oocytes could be
incorporated into the genome. Since the first report of transgenic mice
generated by injecting DNA into the pronucleus of one-cell mouse embryos,
this technique has been immensely useful in creating model organisms for
research purposes (Gordon et al. 1980). Normally, the transgenic construct
consists of a selected enhancer and/or promoter, which may also direct gene
expression to a specific tissue or developmental stage, linked to the sequence to
be expressed. Using this approach, one may directly test in the mouse the role
of selected gene products, dominant negative mutants, or specifically designed
proteins. In theory, once integrated into the murine genome, the injected DNA
can manifest its function. However, as the insertion occurs randomly,
positional variegation effects may be considered, and both the function of
endogenous genes might be affected by the insertion of a transgene as well as
the expression of the transgene itself may also be severely compromised by
surrounding elements.
In 1981, two laboratories reported the isolation of cell lines with the
properties of pluripotent embryonic cells from the culture of early mouse
embryos (Martin 1981, Evans and Kaufman 1981). These cells, called
embryonic stem (ES) cells, after being injected into a young embryo were
capable of colonizing all its tissues including the germ line, thus giving birth to
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chimeras. The ES cell genotype could then be transmitted to future generations.
It was demonstrated that these cells could be genetically modified in vitro,
introducing of a transgene and that the corresponding transgenic mice could be
obtained (Gossler et al. 1986, Robertson et al. 1986). Thus a totally new
method for obtaining transgenic mice was born, considerably widening the
possibility of ‘‘classical’’ transgenesis by microinjection of DNA in the zygote.
Indeed, it became possible for the investigator to use procedures selecting rare
genetic modifications in the ES cells and to obtain the corresponding mutant
mice.
Important research advances have been made using mice as a model for
the study of various biological systems. However, mice are not humans, and
there is a growing need for animal models to carry out in vivo studies of human
cells, tissues and organs. Humanized mice have been developed and are now an
important research tool for the in vivo study of human cells and tissues.
Humanized mice are defined as immunodeficient mice engrafted with
haematopoietic cells or tissues, or mice that transgenically express human
genes. The development of humanized mice is an opportunity to advance in our
understanding of human biological processes, providing new in vivo models to
study human haematopoiesis, immunity system, infectious diseases and cancer
biology (Shultz et al. 2007). For example, humanized mice by transgenic
approach are produced for immunological research. A functional human
immune system was established by the expression of human genes, such as
HLA molecules or immunoglobulins, in immunocompetent mice. HLA
transgenic mice are used to identify antigens presented to T cells by HLA
molecules, whereas human immunoglobulin-transgenic mice are used mainly
to generate human monoclonal antibodies, such as the epidermal growth factor
receptor (EGFR)-specific antibody which have being developed for therapeutic
applications (Bleeker et al. 2004).
1.2.1 Manipulating mouse genome by gene targeting
Gene targeting is a process by which desired changes are introduced
into the nucleotide sequence of a chosen gene (Capecchi 1989). A crucial
advantage of gene targeting approaches for introducing genome modifications
into mice is that the genetic locus to modify can be chosen. Furthermore, the
genetic modification can be precisely designed to address specific biological
questions. Such modifications could include the creation of null mutations, the
introduction of reporter genes to follow gene expression and manipulation to
restrict the effects of a mutation to any desired organs or to any chosen
temporal period during the mouse life (Capecchi 2005).
Mammalian cells have the enzymatic machinery to appropriately
recombine homologous DNA exactly  with their counterparts on the
chromosome, even if this is relatively rare compared with the random
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integration of the same DNA (Smithies et al. 1985, Wong and Capecchi 1986).
Gene targeting is normally carried out in murine ES cells as these cells have
high rates of homologous recombination and are able to contribute to the
germline when re-introduced into mouse embryos at the morula or blastocyst
stage of development (van der Weyden et al. 2002, Bradley 1991, Bradley
1993).
A gene targeting vector will usually consist of a core region containing
the desired genetic modification together with a positive marker that allows the
selection of ES clones that have incorporated the exogenous DNA into their
genome (conferring resistance to antibiotics). This core region is flanked by
two homology arms which are absolute identical to the genomic regions
immediately upstream and downstream of the target site. These arms are
required for homologous recombination to take place, thus introducing the
required modification into the genome. Homologous recombination in ES cells
occurs much less frequently than random integration of DNA. To overcome
this limit, improved strategies are needed to enrich in recombined ES cell
clones and distinguish them from those where random integrations have
occurred. These enrichment strategies usually take advantage of positive and
negative selection markers. The most commonly used positive marker for the
selection of vector incorporating ES clones is the neomycin resistance cassette.
To discriminate homologous recombination from random integrations of the
targeting vector, negative selection is used. A negative marker, such as the
herpes simplex virus type 1 thymidine kinase gene or the diphtheria toxin α-
chain coding region, is placed outside the homology region of the targeting
vector. ES cell clones correctly recombined will not contain this marker, while
most randomly integrated targeting constructs still retain the negative selection
marker, thus permitting acounter selection against randomly integrated clones.
The targeting construct is electroporated into murine ES cells. Positive
and negative selections can be used to enrich for ES cell lines that contain the
desired modified gene. The surviving ES cell colonies are then isolated and
examined for the presence of the targeted allele (to ensure that the desired
recombination event has occurred) by PCR amplification and Southern blot
analysis. A correctly targeted ES clone is then injected into a recipient pre-
implantation mouse embryo, a blastocyst. These embryos are then surgically
transferred to a recipient pseudopregnant foster mother to allow the embryos to
come to term. The resulting pups are then examined for their degree of
chimerism (percentage of the genetic contribution by the injected ES clone).
Male mice showing a high percentage of chimerism are then mated with wild
type mice to check for germ line transmission of the targeted allele in the
offspring (Fig 5).
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Fig 5 – Gene targeting in mouse (Capecchi 2005). Panel A: Isolation of ES cell clones that
contain the desired targeted genomic modification. Panel B: Selected ES cells are used to
generate chimeric mice that are able to transmit the genomic modification to their offspring.
This is accomplished by injecting targeted ES cells into a recipient blastocyst. These embryos
are then transferred to a recipient pseudopregnant foster mother to allow the embryos to
come to term. The extent of the contribution of ES cells to the formation of the chimeric
mouse can be evaluated by visual assessment of coat-colour chimerism. ES cell contribution
to the germ line can be evaluated by observing the coat colour of the progeny that is derived
by mating the chimeric mouse with black mice.
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Gene targeting is most commonly used to create mice bearing null
mutations in any cloned gene (knockout mice) (Fig 6). A knockout
experimental strategy consists of disrupting a chosen gene in the mouse by
replacing the coding exons of the gene with a selectable marker gene. Gene
targeting can also be used to introduce a gene of interest in a specific locus of
the murine genome (knock-in mice). Following homologous recombination
with the chosen target locus, the modified allele expresses the inserted gene in
replacement of the endogenous one. To study a specific mutation in a gene,
knock-in approaches were developed to exchange a mutated DNA sequence for
the endogenous one without gene disruption. Some knock-in strategies rely on
site-specific DNA recombination system using the Cre recombinase from
bacteriophage P1, or the Flp recombinase from S. cerevisiae. Both Cre and Flp
cleave DNA at a distinct target sequence and ligate it to the cleaved DNA of a
second identical site, to generate a contiguous strand. Including Cre or Flip
recombination sites (respectively loxP or FRT) in the targeting vector, it is
possible to replace a gene sequence with a sequence of the investigator’s
choice and to delete unnecessary sequences. Furthermore the genes for Cre or
Flip recombinases can be insert into targeted loci in a way that brings their
expression under the control of the endogenous gene promoter, thus allowing
tissue-specific or temporal specific expression of the enzymes and hence
recombination of loxP or FRT sites that flank the gene of interest.
Fig 6 – Knockout and knock-in strategies. Targeting vectors contain positive and negative
selection genes and two arms of homology with the genomic regions upstream and
downstream the target site. The positive selection gene is flanked by two loxP sites and it can
be removed by Cre-mediated recombination. Knockout strategy allows the deletion of
targeted exon, whereas an exogenous gene is introduced in the targeted locus by knock-in
approach.
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1.2.2 Recombineering to construct targeting vectors
A limitation of gene targeting to modify the murine genome is that it requires
the production of complicated molecular constructs. Traditional genetic
engineering technology uses restriction endonucleases and DNA ligase to cut
and rejoin DNA fragments. Traditional cloning methods break down when
large DNA molecules have to be manipulated. Indeed, even rare restriction
sites occur frequently in DNA sequences containing hundreds of kilobases,
such as bacterial artificial chromosomes (BACs) or P1 artificial chromosomes
(PACs), making the finding of unique sites almost impossible. Furthermore,
the in vitro manipulation of large linear DNAs of this length is extremely
difficult.
The development of phage-based homologous recombination systems
in the last years (Murphy 1998, Muyrers et al. 1999, Yu et al. 2000) has greatly
simplified the generation of targeting constructs, making it possible to engineer
large segments of genomic DNA, such as those carried on BACs or PACs that
replicate at low-copy number in E. coli. Using phage recombination to carry
out genetic engineering has been called “recombinogenic engineering” or
“recombineering” (Muyrers et al. 2001). Recombineering offers exciting new
opportunities for creating inbred mouse models by gene targeting in ES cells.
To perform recombineering, a bacterial strain expressing a
bacteriophage recombination system is required. The phage enzymes can be
expressed from either their own promoter or from a heterologous regulated
promoter. Expressing the genes from their endogenous phage promoter confers
the advantage of tight regulation and coordinate expression, which results in
higher recombination frequencies. This is an important advantage, since in
many cases high recombination frequencies will be essential to obtain a desired
recombinant. After induction of the recombination functions, the modifying
DNA, either a double-stranded PCR product or a synthetic single-stranded
oligonucleotide, is introduced into the phage enzymes expressing strain by
electroporation. Recombinants are obtained either by selection or screening of
the population of cells surviving electroporation.
In λ-mediated recombineering target DNA molecules are precisely
altered by homologous recombination in strains of E.coli expressing phage-
derived protein pairs, either RecE/RecT from the Rac prophage, or Redα/Redβ
from λ phage (Muyrers et al. 1999). These protein pairs are functionally and
operationally equivalent. RecE and Redα are 5´→3´ exonucleases, and RecT
and Redβ are DNA annealing proteins. A functional interaction between RecE
and RecT, or between Redα and Redβ is also required in order to catalyse the
homologous recombination reaction (Fig 7).
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Fig 7 - Mechanism of Red/ET Recombination. Bacteriophage λ contains a homologous
recombination system termed Red, which requires two proteins: Red-α (RecE from Rac
prophage) and Red-β (RecT from Rac prophage). Red-α/RecE are 5’→3’ exonucleases that act
on linear double-strand DNA. Red-β/RecT bind to the 3’ single-strand DNA overhangs created
by Red-α/RecE and stimulate annealing to a complementary strand, promoting strand
invasion and exchange.
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Recombination occurs through homology regions, which are stretches
of DNA shared by the two molecules that recombine. Since the sequence of the
homology regions can be chosen freely, any position on a target molecule can
be specifically altered. Homologous recombination allows the exchange of
genetic information between two DNA molecules in a precise, specific and
faithful manner, qualities that are optimal for DNA engineering regardless of
its size.
Red/ET homologous recombination can efficiently modify
chromosomal or plasmidic DNA in vivo by recombination with linear DNA
electroporated into a cell. The most important aspects of recombineering are
that only short homology segments are required to direct the recombination.
These homologous recombination systems enable large fragments of genomic
DNA to be modified or subcloned in a way that was unimaginable only a few
years ago. The high frequency of recombination offered by these plasmid and
phage systems allows BAC DNA to be manipulated without drug selection.
These recombination systems allow to construct complicated targeting vectors
and generate knock-in and knockout mice (Angrand et al. 1999, Lee 2001).
2. Aims of the study
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2. AIMS OF THE STUDY
The limited species tropism of HCV to human and higher primates
causes the lack of suitable animal models to study hepatitis C. Chimpanzees
are the only established in vivo experimental system, but their use is limited by
restricted availability, expense and ethical aspects. The recent identification of
the minimal human factors that are essential for viral uptake together with the
advances in mouse genome engineering has laid the foundations for creating an
inbred mouse model for HCV.
The aim of our study is the development of a novel mouse strain
humanized for the expression of human HCV receptors. Initially we directed
our attention to the two first entry cellular factors identified, CD81 and SR-BI.
These human transmembrane receptors are involved in HCV entry and their
differences than the murine orthologues contribute to render the mouse cells
not permissive to the HCV infection (Bartosch B et al. 2003b). We designed a
gene targeting strategy to produce humanized mice introducing human CD81
and SR-BI genes in the murine genome, to achieve native expression patterns
of their orthologues.
Human occludin is the final essential HCV entry factor recently
identified by Ploss and colleagues (2009). Their results provide strong
evidence that the expression of human CD81 and occludin in the context of
mouse claudin-1 and SR-BI can be sufficient to overcome the mouse resistance
to HCV entry. Therefore we added occludin to the chosen human receptors for
producing novel knock-in mouse strains.
Our humanized mouse models could allow HCV glycoproteins
mediated entry and could be an important tool for in vivo studying of virus-host
interactions.
3. Materials and Methods
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3. MATERIALS AND METHODS
3.1 Targeting vectors
Targeting vectors to insert human CD81, SR-BI and OCLN genes in the
murine genome were constructed using both traditional genetic engineering
and Red/ET recombineering technologies. For each gene, human coding
sequence (hCDS) was inserted in a modified pL451 plasmid (NCI- Frederick),
that contains SV40 polyadenilation signal (pA) followed by neomycin
resistance cassette (NeoR, constituted by FRT - PGK promoter - EM7 promoter
- neomycin resistance gene – bGH pA - FRT) (pL451-pA); the hCDS was
specifically digested and ligated upstream SV40 pA. The human gene cassette
(hBOX, constituted by CDS – SV40 pA – NeoR) was amplified by high-fidelity
PCR (AccuPrime Pfx – Invitrogen) using specific primers designed with 50 bps
homology arms to their 5’. These arms mediated homologous recombination in
Red/ET expressing E. Coli strain that allowed the insertion of hBOX in a
specific site of the BAC including murine orthologous gene. The region of the
recombined BAC constituted by the hBOX flanked by two asymmetric murine
genomic arms was subcloned in pBluescript II KS+ (pBS, Agilent
Technologies) by Red/ET recombineering: pBS was amplified by PCR using
primers designed with short segments homologous to the upstream and
downstream ends of interesting BAC region, and introduced in recombined
BAC containing bacteria by electroporation. Red/ET recombination led to the
retrieving of the BAC region of interest in pBS and the targeting vector was
obtained (Fig 8). Plasmids and primers used to construct the three targeting
vectors are indicated in table 1 (Tab 1). All PCR primers used in our study
were designed using Vector NTI software (Invitrogen). Every cloning step
including PCR amplification was verified for nucleotide mismatches by direct
sequencing analysis of plasmids (Stazione Zoologica A. Dohrn, Napoli).
3.2 Gene targeting and generation of humanized knock-in mice
The targeting vectors were linearized with Eco RV (CD81 and OCLN
vectors) and with Pvu I (SR-BI vector), and introduced in murine ES cells by
electroporation (MicroPorator MP-100 Digital Bio).
The ES cells were maintained in Dulbecco’s Modified Eagle’s Medium
(DMEM) supplemented with 15% FBS (HyClone), 2 mM L-Glutamine
(Gibco), 1X NEAA (Gibco), 50 µg/ml Penicillin/Streptomycin (Gibco), 0.1
mM β-mercaptoethanol (Sigma), 1000 U7ml LIF (Chemicon), 1 mM Sodium
Pyruvate and 400 µg/ml, Geneticin (G418, Gibco).
ES cells that survived G418 selection were screened for correct
targeting by PCR (Tab 2) and Southern blotting as described in section 4. The
correctly targeted ES cell clones were electroporated with a FLPe-expressing
plasmid (pCAGGS-FLPe) to delete the NeoR by recombination between the
FRT sites.
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Correctly targeted ES clones, with NeoR or with NeoR removed, were
micro-injected into C57BL/6 blastocysts to generate chimeric mice. Chimeric
male mice were bred with C57BL/6 females and tested for germ line
transmission. The germ line transmitted F1 mice were further inter-crossed to
generate mice used in this study. Mice with NeoR were further crossed with
transgenic mice expressing FLPe recombinase protein in both somatic and
germ cells under the control of human ACTB promoter (Rodriguez et al. 2000).
Fig 8 – Targeting vector construction by recombineering strategy. Panel A: hCDS (green bar)
was inserted by traditional cloning in pL451-pA plasmid, upstream SV40pA (red bar) and
neomycin cassette (closed triangles indicate FRT sites, grey arrow PGK promoter, purple
arrow prokaryotic EM7 promoter). hBOX was amplified by PCR with primers with 5’ short
homology arms (yellow and blue bars). Panel B: hCDS PCR product was introduced in Red/ET
bacteria containing a specific bMQ BAC, and inserted in place of the murine exon sequence in
the BAC by homologous recombination between short arms. Neomycin resistant bacteria
colonies were selected and screened for correct recombination. Panel C: Recombined BAC
region including hBOX flanked by two asymmetric homology arms (black bars) was subcloned
in pBS:  primers with 5’ short homology arms (light blue and green bars) were used to amplify
pBS, and the PCR product was introduced in Red/ET bacteria containing recombinant BAC.
Red/ET homologous recombination mediated the incorporation of BAC region in pBS. Only
the plasmid correctly recombined conferred ampicillin resistance to the bacteria.
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Tab 1 – Plasmids and primers used to construct CD81, SR-BI and OCLN targeting vectors.
Tab 2 – PCR primers used to screen CD81, SR-BI and OCLN targeted ES cell clones. Genomic
DNA was isolated from 96-well plates ES clones (section 3.3), and PCR analysis was performed
using Expand Long Template PCR System (Roche), according with the manufacturer’s
procedure.
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3.3 Southern blotting
To analyse targeted ES cell clones by Southern blotting,  genomic DNA
was isolated from Es cell clones in 6-well plates by cell lysis (10 mM Tris pH
7.5, 10 mM EDTA pH 8, 10 mM NaCl, 0,5 % sarcosyl with 1.0 mg/ml
Proteinase K; 60°C 14 h) and ethanol precipitation (75 µM NaCl, EtOH 98%).
ES cell clones genomic DNA was digested as described in section 4,
and separated by 0.7% agarose gel electrophoresis. The probes were labelled
with digoxigenin using PCR DIG Probe Synthesis Kit (Roche). Southern
blotting was carried out with Hyond-N+ nylon membrane (Amersham), using
alkaline blotting protocol recommended by the supplier. Hybridization and
detection were performed in accordance with the DIG system protocols
(Roche).
3.4 PCR mice genotyping
Mice and 10.5 embryos described in our study were genotyped by PCR
analysis of genomic DNA isolated respectively from tail biopsies and yolk
sacs. Tail biopsies and yolk sacs were lysed (50 mM Tris pH 7.5, 100 mM
EDTA pH 8, 100 mM NaCl, 1% SDS, 1.0 mg/ml Proteinase K; 55 °C 14 h)
and DNA was precipitated (2 M NaCl, 50% Isopropanol). PCR genotyping was
designed as described in section 4, using primers indicated in table 3 (Tab 3).
To genotype preimplantation embryos, each embryo was collected in PCR tube
in dry ice. They were heat shock lysed transferring the tubes from dry ice to
room temperature. Nested PCR was performed on the whole embryo to
determine its genotype.
Tab 3 – PCR primers used to genotype CD81, SR-BI and OCLN humanized knock-in mice.
(O9’, O10’, O11’ are used to perform the first reactions in nested PCR to genotype
preimplantation embryos).
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3.5 Reverse Transcription (RT)-PCR and real time PCR
Different mouse tissues (kidney, liver, lung, tail) was disrupted and
homogenized by TissueLyser (Qiagen) and total RNA was isolated by Trizol
reagent extraction (Invitrogen). First strand cDNA synthesis was perfomed
using M-MuLV Reverse Transcriptase RNase H- and oligo dT primers
(Finnzymes), according with the manufacturer’s procedures.
RT-PCR and real time PCR primers were designed to amplify specific regions
of wild type and humanized transcripts (Tab 4), as described in section 4. RNA
samples without the addition of reverse transcriptase were also included as
negative PCR controls.
RT-PCR was performed using high-fidelity Taq polimerase (Phusion,
Finnzymes) and purified PCR products (Qiaex II PCR purification Kit, Qiagen)
were analysed by direct sequencing (Stazione Zoologica A Dohrn, Napoli).
The amplification efficiency of primer pairs used for real time PCR was
preliminary calculated by cDNA standard dilutions reactions. Real time PCR
was performed using Power SYBR Green PCR reagents and ABI Prism 7900
Real Time PCR System (Applied Biosystems). Threshold cycle values (Ct)
were determined and analyzed by Applied Biosystems software.  To calculate
mRNA levels of specific genes Ct values were corrected for primers efficiency
and normalized for the housekeeping GAPDH, according to the Pfaffl’s model
(Pfaffl 2001).
Tab 4 – RT-PCR and real time PCR primers.
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3.6 Western blotting
Mouse protein extract for electrophoresis was generated lysing 1 mg of
liver by TissueLyser (Qiagen) in lysis buffer (20 mM TrisHCl pH 8, 150 mM
NaCl, 2 mM EDTA, 1% TRITON X 100, 1 mM DTT, 1mM PMSF, 1 mM
Na3VO4, 1mM NaF, 2 mM AEBSF, 130 μM Bestatin, 14 μM E-64, 1 μM
Leupeptin, 0.3 μM Aprotinin). Samples were run on 4-12% NuPAGE
polyacrylamide gradient gels (Invitrogen) and blotted onto Immobilon-P PVDF
membrane (Millipore) at 8V/cm 1 hour  in 25 mM Tris-HCl:150 mM glycine buffer,
pH 8.3 containing 10% methanol. Blots were blocked in PBS: 0.3% Tween 20: 5%
non-fat milk, before incubating with rabbit polyclonal anti-human occludin antibody
(Invitrogen #71-1500) and mouse monoclonal anti-β-actin (Sigma #A2228) 1 µg/ml in
blocking buffer for 1 hour. Antibody binding was detected with HRP-labelled
secondary antibody (Amersham) diluted in blocking buffer. Blots were developed
using ECL chemiluminescence (Pierce).
3.7 Murine primary hepatocytes isolation
4 month old mice were anesthetized with Avertin 2.5 (Sigma) and the
abdomen opened using Wagner scissors 10.5 cm in order to expose the bowel.
The hepatic vena porta was isolated and cleaned from the surrounding fat
tissue and then clumped with a stitch at the caudal end. A small  incision made
with 2.5 mm spring scissors allowed the insertion of a cateter, then secured to
the vein with a  second stitch. Perfusion was performed with a 50-60 ml of a
pre-perfusion solution (0.9% NaCl, 0.05% KCl, 0.2% HEPES, 0.08 mg/ml
EGTA) and subsequently with a 50-60 ml of a digestion solution (0,6% NaCl,
0.05% KCl, 1.2% HEPES, 0.07% CaCl2 and Collagenase type IV from Sigma
0.32 mg/ml) at a flow rate of 5 ml/min. Digestion was stopped when the liver
changed both colour and texture. After removing the gall bladder, the liver was
minced with a razor blade and homogenized with a pipette device and
subsequently filtered through a 70 µm strainer. The homogeneous suspension
was then washed (600 rpm, 4’), resuspended in 3 ml of William’s Complete
Medium E (Gibco) and then loaded on a 37.5 % Percoll cushion to isolate only
the viable cells from cell debris and other undesired digestion products (1050
rpm, 3’). Viable isolated hepatocytes were counted in a Burker chamber and
then seeded in gelatine coated 6 wells plates at the desired concentration.
Total RNA was extracted from 48 hours cultured primary cells by
Trizol reagent protocol (Invitrogen) and it was retro-transcribed using
QuantiTect Reverse Transcription kit (Qiagen), according with the
manufacturer’s procedures. RT-PCR was performed to amplify two hepatic
markers, albumin (5’CATACGATGAGCATGCCAAAT 3’; 5’GCACACAACTTATCTCCAAAAAGA 3’)
and α-fetoprotein (5’ACCTTTACCCAGTTTGTTCCG 3’; 5’ACAAATTTCATCCAGAAACACAGATA
3’).
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3.8 HCV pseudotypes infection assay
Primary hepatocytes isolated from our mice were plated on gelatine
0.2% (Sigma) coated 6-wells at 80x103 cells/well and cultured in William’s
Supplemented Medium (William’s Medium E, 4% inactivated FBS, 1%
pen/strep,  1% Glutamax,  EGF 50 ng/mL, Insulin 1 ug/mL, Transferrin 10
µg/mL, Hydrocortisone 1.3 ug/mL) 48 hours before infection. Hep3B and
Hepa1.6 cell lines were seeded on 6-wells at 120x103 cells/well and cultured on
DMEM (10% FBS, 1% pen/strep, 1% Glutamax) 24 hours before infection.
293T cells were transfected using Calcium Phosphate with 12.5 µg of
pCMV-E1E2 (from Granier C, Viral Envelopes and Retrovirus Engineering)
and 12.5 µg of pNL4-3.Luc.R-E- (NIH AIDS Reaserch and Reference Reagent
Program) and 12 hours after transfection fresh culture media was added. 48
hours and 72 hours after transfection viral surnatants from 5 transfections were
collected. They were pooled and filtered through a 0,22 µm syringe driven
filter units. To help viral attachment on cell surface, polybrene 4 ng/µl was
added and then the viral surnatant was dispensed 3 ml/well on primary
hepatocytes, Hep3B and Hepa1.6 cells. To further improve infection yeld the
plates were then spinoculated at 1200 g for 90’ at 37°C. 24 hours after the last
round of infection, cells were collected and lysed; luciferase assay (Promega)
was performed. Bradford assay (Biorad) allowed to normalize the luciferase
values for the total protein amount of each sample.
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4. RESULTS AND DISCUSSION
4.1 Generation of humanized CD81 knock-in mouse
The tetraspanin CD81 has been proposed as a first putative cellular
receptor involved in hepatitis C virus (HCV) entry into the host cell. A soluble
form of HCV glycoprotein E2 (sE2) binds to human cells and was used to
identify CD81 as an HCV receptor molecule (Pileri et al. 1998). The large
extracellular loop of human CD81 binds to sE2 and this binding appears to be
species-specific, as sE2 does not bind mouse CD81 (Flint et al. 2006). Non-
permissive human hepatoma cell lines, which do not express CD81, become
susceptible to HCV pseudoparticle infection upon ectotopic expression of
CD81 after transduction (Bartosch et al. 2003b, Cormier et al. 2004b, Lavillette
et al. 2005, Zhang et al. 2004). The binding of sE2 to the liver tissue was
confirmed in transgenic mice expressing human CD81. However the
expression of human CD81 alone in transgenic mice is not sufficient to confer
susceptibility to HCV infection (Masciopinto et al. 2002). There are at least
two possible reasons for this failure: other human receptors are required, and
the exogenous genes have to be regulated according to the native expression
patterns of their orthologues. The knock-in approach allows to insert an
exogenous gene in a desired specific site of the murine genome, therefore it is
possible to substitute the murine genes with their human orthologues for the
putative HCV receptors. We chose this strategy to produce novel mouse strains
expressing human HCV receptors, including CD81.
CD81 human and murine genes are highly homologous: they are both
constituted by 8 exons and they share the 87% of the coding sequence and the
92% of the amino acid sequence. We manipulated the murine genome so that
CD81 gene was translated in the human protein. Using a gene targeting
approach, we created a CD81 chimeric gene by inserting in the murine gene the
human coding sequence (CDS) beginning at the position of the first codon
which differs between the two species (AA43) (Fig 9).
We designed and constructed a molecular vector to modify CD81
murine gene by homologous recombination in mouse embryonic stem (ES)
cells (Fig 10). This targeting vector was constituted by two asymmetric regions
of genomic sequence, the homology arms, obtained from a 129S7/SvEv mouse
bMQ BAC comprising the genomic locus of CD81. These homology arms
flanked the partial CDS of human CD81, from the nucleotide 127 to the stop
codon, followed by SV40 polyadenilation signal. The neomycin resistance
gene, under the control of PGK promoter, was included by two FRT sites
(NeoR cassette) and inserted downstream the human CDS. The targeting vector
was linearized and introduced into the murine R1/129/Sv ES cell line (Nagy et
al. 1993) by electroporation. The recipient clones were then screened for
correct targeting by PCR analysis (Fig 11). On 288 G418 selected clones we
found 8 correctly recombined clones by PCR analysis. These clones were
further analyzed by Southern blotting to verify the correct recombination and
the absence of unspecific integrations of the exogenous DNA into their genome
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(Fig 12). The correct targeting was confirmed by Southern blotting for every 8
clones, showing no random integration.
Fig 9 – CD81 human and murine proteins alignment and chimeric transcript. Panel A: the
protein alignment between human and murine CD81 sequences is represented: yellow
indicates identical amino acids, green similar amino acids, white different “non-similar” amino
acids. The red box indicates the first amino acid substitution between human and murine
sequences (N43S), corresponding to the missense nucleotide substitution A128G, as indicated
by the arrow. Panel B: to humanize the mouse for CD81 protein, its human coding sequence
(CDS) was inserted in the second exon of the murine orthologous gene (pink bar), exactly
from the first missense substitution (A128G) to the stop codon (green bar), followed by SV40
polyadenilation signal (red bar).
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Fig 10 – Gene targeting strategy to humanize CD81 murine gene. A targeting vector to insert
the human CDS of CD81 in the murine locus was constructed: two asymmetric homology
regions (5’ arm of 5 kb, and 3’ arm of 3 kb) flank partial human CD81 CDS (from the
nucleotide 127 to the stop codon) followed by SV40 polyadenilation signal (pA) and the
neomycin resistance gene (NeoR) included by two FRT sites (closed triangles). These
exogenous elements were inserted by homologous recombination in the murine locus,
replacing the second exon, so that the human sequence was in frame with the murine one.
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A
Fig 11 – CD81 targeted murine ES cell screening by PCR analysis. G418 resistant cell clones
were screened for the correct targeting by PCR analysis. Panel A: CD81 wild type and
recombinant loci are represented; the sense primer (red rightwards arrow) anneals on the
genomic sequence within the 5’ homology arm, the antisense primer (red leftwards arrow)
anneals on the genomic sequence downstream the 3’ arm. They amplify a 3.6 kb product on
the wild type allele and a 6.2 kb product on the targeted allele. Panels B and C: PCR results are
reported for nine clones. The clones 1-8 showed both the wild type and the recombinant
products, so they were correctly targeted. The clone 9 had only the wild type product and it
did not correctly recombine (B). ES clones genomic DNA was further digested with Sac I
before PCR: Sac I cut outside the wild type amplified region and inside the recombinant
amplified region, as shown in panel A. After this digestion the targeted PCR product
disappeared, demonstrating its specificity (C).
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A
Fig 12 – Southern blot analysis of CD81 humanized ES cells. To verify the correct
recombination and the absence of unspecific integrations, targeted ES clones were analyzed
by Southern blotting. Panel A: CD81 wild type and recombinant loci are represented;
oligonucleotide probe annealed on the 3’ homology arm genomic sequence and after Sac I
digestion it detected a wild type restriction product of 6.7 kb and a recombinant restriction
product of 4 kb (or 3.8 kb when neomycin cassette was removed). Panel B: Southern blotting
results are reported for a correctly targeted clone, before and after the FLPe treatment, m/h
(Neo+) and m/h respectively. A wild type clone, m/m, was reported too.
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One targeted ES clone was microinjected in C57BL/6 blastocyst to
generate chimeric mice. These chimeras were mated with C57BL/6 wild type
mice and their offspring derived entirely from 129/Sv injected cells, as
indicated from their coat color (agouti). The genomic modification produced in
the embryonic cells was successfully transmitted to the germ line.
The mice were genotyped for the specific knock-in allele performing a
three primers PCR on genomic DNA extracted from their tails biopsies (Fig
13).
The produced knock-in mice still contained the NeoR cassette, therefore
they were later bred with transgenic mice expressing FLPe recombinase protein
in both somatic and germ cells under the control of human ACTB promoter
(Rodriguez et al. 2000) to remove the NeoR cassette.
More than 60 mice were produced from the mate of the chimera with
wild type mice and with FLPe transgenic mice, and about the half presented
heterozygous genotype for CD81 locus, CD81 murine / CD81 human (CD81
m/h), according to the Mendelian ratio. Heterozygous CD81 m/h mice were
viable, with normal growth and exhibited no overt gross phenotypes.
A
Fig 13 – Humanized CD81 knock-in mice PCR genotyping. Genomic DNA was extracted from
mice tails to determine their genotype by PCR. Panel A: CD81 wild type and recombinant loci
are represented; the sense primer (red arrow) amplifies a 604 bps product with one antisense
primer (blue arrow) on the wild type allele, and a 421 bps product with the other antisense
primer (yellow arrow) on the targeted allele. Panel B: Genotyping results are reported for a
wild type mouse (m/m) and a heterozygous mouse (m/h).
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4.2 CD81 expression in humanized CD81 knock-in mouse
The nucleotide sequence coding the human form of CD81 was
introduced in the genome so that the second exon of the murine orthologous
gene was deleted (Fig 10). The transcription of the exogenous sequence is
regulated by the promoter of CD81 murine gene; SV40 polyadenylation signal
was inserted downstream the human CDS to allow transcription termination
and to stabilize the mRNA (Proudfoot et al. 1991). The targeted allele
transcription leads to the production of CD81 chimeric transcript instead of the
murine endogenous one. In CD81 heterozygous mice both the wild type and
humanized transcripts are produced; when homozygous mice will be generated
only the humanized gene will be transcribed.
To verify if the gene manipulation corresponded to the expected
phenotype, we performed RT-PCR analysis of CD81 transcripts (Fig 14). Total
RNA was extracted from different CD81 expressing tissues (lung, liver,
kidney). Heterozygous CD81 m/h and wild type CD81 m/m total RNA samples
were collected and treated to completely remove genomic DNA contamination.
They were retro-transcribed and then used as template for specific PCR. We
designed two reactions to discriminate humanized transcript from the murine
wild type one. Both recombinant and wild type products were found in
heterozygous samples, demonstrating that the exogenous gene for human
CD81 was expressed. We also determined the sequence of the amplified
products and their specificity was confirmed (Fig 7). As figure 15 shows,
CD81 was expressed as both wild type and human transcripts in heterozygous
mouse liver. These data suggest that a novel humanized CD81 murine line was
permanently established.
A
B
Fig 14 – RT-PCR analysis of CD81 transcripts.
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Fig 14 – RT-PCR analysis of CD81 transcripts. Panel A: The structure of wild type and
recombinant CD81 transcripts is schematically shown. Pink bars represent murine exons,
green bar represents the inserted human CDS, red bar represents SV40 polyadenylation
signal. PCR was performed using a sense primer annealing on the murine sequence shared by
both wild type and recombinant transcripts (pink rightwards arrows) and two different anti-
sense primers: one annealing only on the wild type transcript (pink leftwards arrow), the
other annealing only on the human sequence (green leftwards arrow). Panel B:  PCR results
on liver cDNA were reported. Liver was dissected from wt mice (m/m) and from CD81
heterozygous mice (m/h). RNA control samples, in which no retrotranscriptase was added (-
RT), were also included (lanes 2, 4, 6, 8).  Amplification using the sense primer paired with the
antisense primer annealing only on the human sequence produced the specific 723 bps
fragment for m/h and no one for m/m (lanes 1, 3), while the reaction with the antisense
primer annealing only on the wild type transcript produced the specific 1008 bps fragment for
both m/h and m/m (lanes 5, 7). No product was observable in –RT controls.
Fig 15 – Sequence analysis of CD81 RT-PCR products. Liver cDNA from heterozygous CD81
m/h mouse was specifically amplified to discriminate humanized transcript from the wild type
one. Two different PCR products were obtained and they were further mixed and sequenced.
Only a small region of the whole sequence is reported: yellow arrows indicate double picks
corresponding to the nucleotide substitutions between human and murine sequences. These
results demonstrated the liver expression of both wild type and humanized CD81 transcripts
in the heterozygous mouse.
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4.3 Generation of humanized SR-BI knock-in mouse
Scavenger receptor class B member 1 (SR-BI) has been proposed to act
as a putative HCV entry molecule on the basis of its reactivity with HCV sE2
(Scarselli et al. 2002). SR-BI binding to sE2 appears to be species-specific, as
mouse SR-BI does not bind sE2. Antibodies against SR-BI also significantly
reduce HCV pseudoparticles infectivity (Bartosch et al. 2003b).
Similar to CD81, SR-BI is a cellular receptor involved in HCV entry
and the differences between the murine protein and the human one could
contribute to render the mouse cells not permissive to the HCV psuedoparticles
infection. We decided to produce a novel mouse strain expressing human SR-
BI, as done for CD81. Using a similar gene targeting approach, we inserted
SR-BI human CDS in murine genome to replace the orthologous gene.
SR-BI human and murine genes are both constituted by 13 exons and
they share the 80% of the coding sequence and the 80% of the amino acid
sequence. A chimeric gene was created inserting the complete human CDS of
SR-BI in the murine gene replacing the first coding exon, exactly from the start
codon (Fig 16).
Fig 16 – SR-BI human and murine proteins alignment and chimeric transcript. Panel A: the
protein alignment between human and murine SR-BI sequences is represented: yellow
indicates identical amino acids, green similar amino acids, white different “non-similar” amino
acids. Panel B: to humanize the mouse for SR-BI protein, its human CDS was inserted in the
first exon of the murine orthologous gene (pink bar), exactly from the start codon to the stop
codon (green bar), followed by SV40 polyadenilation signal (red bar).
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We designed and constructed a targeting vector to modify SR-BI murine gene
by homologous recombination in mouse ES cells (Fig 17). Two asymmetric
homology arms, obtained from a 129S7/SvEv mouse bMQ BAC comprising
the genomic locus of SR-BI, flanked the SR-BI CDS followed by SV40
polyadenilation signal. The neomycin resistance cassette was also included
downstream the human gene. The targeting vector was linearized and
electroporated into the murine W4/129S6/SvEv ES cell line (Auerbach W et al.
2000). The recipient clones were then screened for correct targeting by PCR
analysis (Fig 18). On 96 G418 selected clones we found 2 correctly
recombined clones by PCR analysis. To verify the absence of random
integrations, targeted clones were further analyzed by Southern blotting (Fig
19). The correct targeting was confirmed by Southern blotting for both clones,
and no random integration was observed.
Fig 17 – Gene targeting strategy to humanize SR-BI murine gene. A targeting vector to insert
the human CDS of SR-BI in the murine locus was constructed: two asymmetric homology
regions (5’ arm of  2 kb, and 3’ arm of 3 kb) flank human SR-BI complete CDS followed by
SV40 polyadenilation signal (pA) and the neomycin resistance gene (NeoR) included by two
FRT sites (closed triangles). These exogenous elements were inserted by homologous
recombination in the first murine exon, exactly from the start codon.
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Fig 18 – SR-BI targeted murine ES cell screening by PCR analysis. G418 resistant cell clones
were screened for the correct targeting by PCR analysis. Panel A: SR-BI wild type and
recombinant loci are represented. Two different reactions were designed to amplify a
genomic region including the 5’ homology arm (2.8 kb) and another region including the 3’
homology arm (3.5kb). Both the PCR primers pairs annealed outside the homology arms, one
primer of each pair on the wild type genomic sequence (red arrows), the other on the
inserted exogenous sequence (blue arrows). Panel B: PCR results are reported for three
clones. The specific 5’ product was amplified for every three clones, while only clones 1 and 3
presented the specific 3’ product. A positive control was also included and it consisted of
modified BAC used to construct the targeting vector.
4. Results and Discussion
42
A
Fig 19 – Southern blot analysis of SR-BI humanized ES cells. To verify the correct
recombination and the absence of unspecific integrations, targeted ES clones were analyzed
by Southern blotting. Panel A: SR-BI wild type and recombinant loci are represented;
oligonucleotide probe annealed on the 5’ homology arm genomic sequence and after Pvu II
digestion it detected a wild type restriction product of 7.3 kb and a recombinant restriction
product of 4.7 kb. Panel B: Southern blotting results are reported for the PCR analyzed clones
shown in figure 18 (1-3) and for a wild type clone (4). Clones 1 and 3 presented only the wild
type and the specific recombinant products, while clone 2 presented more fragments
corresponding to random integrations.
One targeting ES clone was microinjected in a C57BL/6 blastocyst to
generate chimeric mice that transmitted the correct modification to the germ
line. A three primers PCR performed on genomic DNA extracted from tail
allowed to determine the mice genotype for the SR-BI targeted allele (Fig 20).
The heterozygous knock-in mice, containing the neomycin resistance gene,
were interbred with the available FLPe transgenic mice.
21 mice were generated from the mate of the chimera with wild type
mice, and about the half presented heterozygous genotype for SR-BI locus
(SR-BI m/h), according to the Mendelian ratio. Heterozygous SR-BI m/h mice
were viable, with normal growth and exhibited no overt gross phenotypes.
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Fig 20 – Humanized SR-BI knock-in mice PCR genotyping. Genomic DNA was extracted from
mice tails to determine their genotype by PCR. Panel A: SR-BI wild type and recombinant loci
are represented; the sense primer (red arrow) amplifies a 531 bps product with one antisense
primer (blue arrow) on the wild type allele, and a 731 bps product with the other antisense
primer (yellow arrow) on the targeted allele. Panel B: Genotyping results are reported for a
wild type mouse (m/m) and a heterozygous mouse (m/h).
4.4 SR-BI expression in humanized SR-BI knock-in mouse
SR-BI murine locus was modified inserting the complete human CDS,
followed by a polyadenilation signal, in the place of the first exon by
homologous recombination in ES cells (Fig 17). The transcription of this
modified gene produces a SR-BI chimeric transcript constituted by murine five
prime untranslated region (5’ UTR), the human CDS and SV40 polyadenilation
signal (Fig 21 A). In humanized SR-BI heterozygous mice both the wild type
and chimeric transcripts are produced; when homozygous mice will be
generated only the humanized gene will be transcribed.
RT-PCR was performed to analyze SR-BI transcripts, as done for
humanized CD81 mice (Fig 21). Liver was dissected from heterozygous SR-BI
m/h and wild type SR-BI m/m mice and total RNA was extracted and treated to
completely remove genomic contamination.  Two different RT-PCRs were
designed to specifically discriminate humanized chimeric transcript and murine
wild type transcripts. Both wild type and chimeric products were found in
heterozygous samples, demonstrating that the exogenous gene for human SR-
BI was expressed. We also determined the sequence of the amplified products
and their specificity was confirmed (Fig 22).
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Fig 21 – RT-PCR analysis of SR-BI transcripts. Panel A: The structure of wild type and chimeric
SR-BI transcripts is schematically shown. Pink, green and red bars represent murine exons,
human CDS and SV40 polyadenylation signal, respectively. RT-PCR performed using primers
annealing only on the murine sequence (pink arrows) amplified a wild type product of 1334
bps; amplification using the sense primer annealing on the human sequence (green arrow)
and the antisense primer on the polyadenylation signal (red arrow) produced a chimeric
fragment of 897 bps. Panel B: PCR on liver cDNA were reported. Liver was dissected from wt
mice (m/m) and from SR-BI heterozygous mice (m/h). RNA control samples, in which no
retrotranscriptase was added (-RT), were also included (lanes 2, 4, 6, 8). RT-PCR using
chimeric transcript specific primers amplified the 897 bps product only for m/h (lanes 1, 3),
while the reaction with wild type specific primers amplified the 1334 bps product for both
m/h and m/m (lanes 5, 7). No product was observable in –RT controls.
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Fig 22 – Sequence analysis of SR-BI RT-PCR products. Liver cDNA from heterozygous SR-BI
m/h mouse was specifically amplified to discriminate humanized transcript from the wild type
one. Two different PCR products were obtained and sequenced. Only a small region of whole
sequence is reported: yellow arrows indicate the nucleotide substitutions (numbered 1-4),
purple arrows nucleotide insertions between human and murine sequences. These results
demonstrated the liver expression of both wild type and humanized SR-BI transcripts in the
heterozygous mouse.
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4.5 Generation of humanized occludin knock-in mice
The tight junction protein occludin (OCLN) has been identified as a
new HCV entry factor essential for HCV infection together with the already
known HCV receptors CD81, SR-BI and CLDN-1 (Ploss et al. 2009, Liu et al.
2009). The experiments by Ploss et al. showed that non-HCV-permissive
human and non-human cell lines became susceptible to HCV when all four
molecules are expressed. Their results provide strong evidence that OCLN is
the final essential entry factor for HCV. Moreover they speculated that the
expression of human CD81 and OCLN in the context of mouse CLDN-1 and
SR-BI can overcome the major block to HCV replication in murine cells,
providing a clear foundation upon which a mouse model for HCV infection can
be obtained (Nature 2009;457:797-98,882-86). These conclusions urged us to
produce another humanized mouse strain for the last identified essential HCV
receptor.
OCLN human and murine genes are both constituted by 9 exons and
they share the 86% of the coding sequence and the 89% of the amino acid
sequence. A chimeric gene was created inserting the complete human CDS of
OCLN in the murine gene replacing the first coding exon, exactly from the
start codon (Fig 23).
Fig 23 – OCLN human and murine proteins alignment and chimeric transcript. Panel A: the
protein alignment between human and murine OCLN sequences is represented: yellow
indicates identical amino acids, green similar amino acids, white different “non-similar” amino
acids. Panel B: to humanize the mouse for OCLN protein, its human CDS  was inserted in the
second exon of the murine orthologous gene (pink bar), exactly from the start codon to the
stop codon (green bar), followed by SV40 polyadenilation signal (red bar).
A targeting vector to insert the human gene in the place of the murine
one by homologous recombination in ES cells was designed and constructed
similarly to those described for CD81 and SR-BI (Fig 24). The targeting vector
was linearized and electroporated into the murine W4/129S6/SvEv ES cell line
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(Auerbach et al. 2000). G418 resistant ES cell colonies were screened by PCR
analysis (Fig 25). On 288 G418 selected clones we found 6 correctly
recombined clones by PCR analysis. To verify the absence of unspecific
random integrations, targeted clones were further analyzed by Southern
blotting (Fig 26). The correct targeting was confirmed by Southern blotting for
every 6 clones, and no random integration was observed.
Fig 24 – Gene targeting strategy to insert the human OCLN gene in the murine locus. A
targeting vector to insert the human CDS of OCLN in the murine locus was constructed: two
asymmetric homology regions (5’ arm of  5 kb, and 3’ arm of 3.3 kb) flank human OCLN
complete CDS followed by SV40 polyadenilation signal (pA) and the neomycin resistance gene
(NeoR) included by two FRT sites (closed triangles). These exogenous elements were inserted
by homologous recombination in the second murine exon, exactly from the start codon.
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Fig 25 – OCLN targeted murine ES cells screening by PCR analysis. G418 resistant cell clones
were screened for the correct targeting by PCR analysis. Panel A: OCLN wild type and
recombinant loci are represented. Two different reactions were designed to amplify a
genomic region including the 5’ homology arm (5.8 kb) and another region including the 3’
homology arm (3.8kb). Both PCR primers pairs annealed outside the homology arms, one
primer of each pair on the wild type genomic sequence (red arrows), the other on the
inserted exogenous sequence (blue arrows). Panel B: PCR results are reported for seven
clones. The specific products were amplified for six clones, while clone 5 presented only an
unspecific product at 3’ PCR. A positive control was also included and it consists of modified
BAC used to generate the targeting vector.
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Fig 26 – Southern blot analysis of humanized OCLN ES cells. To verify the correct
recombination and the absence of unspecific integrations, targeted ES clones were analyzed
by Southern blotting. Panel A: OCLN wild type and recombinant loci are represented;
oligonucleotide probe annealed on the 3’ homology arm genomic sequence and after Hind III
digestion it detected a wild type restriction product of 8.5 kb and recombinant restriction
products of 5.6 kb and 3.8 kb, before and after FLPe treatment respectively. Panel B:
Southern blotting results are reported for a correctly targeted clone, before and after the
FLPe treatment, m/h (Neo+) and m/h respectively. A wild type clone, m/m, was reported too.
Chimeric mice were generated by blastocyst injection of one targeted ES clone
containing the NeoR cassette or with the Neo cassette removed by transient
transfection and expression of FLPe recombinase. These chimeras were bred
with C57BL/6 wild type mice to generate heterozygous neoOCLN and OCLN
mice respectively as demonstrated by PCR genotyping (Fig 27).
Mice containing the NeoR cassette flanked by FRT sites were further
bred with the available FLPe transgenic mice, to generate heterozygous mice in
which the NeoR cassette has been removed (herein referred to as OCLN-2
mice).
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Fig 27 – Humanized OCLN knock-in mice PCR genotyping. Genomic DNA was extracted from
mice tails to determine their genotype by PCR. Panel A: OCLN wild type and recombinant loci
are represented; the sense primer (red arrow) amplifies a 445 bps product with one antisense
primer (blue arrow) on the wild type allele, and a 603 bps product with the other antisense
primer (yellow arrow) on the targeted allele. Panel B: Genotyping results are reported for a
heterozygous mouse (m/h) and a wild type mouse (m/m).
4.6 OCLN expression in humanized OCLN knock-in mouse
To generate a humanized mouse for the occludin protein, we modified
the murine genome introducing the nucleotide sequence coding for the human
occludin in the place of the first coding exon of the murine orthologous gene.
This genomic modification was transferred in mouse germ line so that a new
humanized occludin murine line was permanently established.
To verify if the gene manipulation corresponded to the expected
phenotype, we performed RT-PCR analysis of occludin transcripts (Fig 28).
Total RNA extracted from different tissues of heterozygous OCLN m/h mice
was retro-transcribed and then used as template for specific PCRs. We
designed two reactions to discriminate humanized transcript from the murine
wild type one. Both recombinant and wild type products were found in
heterozygous samples, demonstrating that the exogenous gene for human
occludin was expressed. We also determined the sequence of these PCR
products and their specificity was confirmed (Fig 29). As shown in figure 28
shows, OCLN was expressed as both wild type and human transcripts in
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heterozygous mouse liver. These data expression demonstrated the
effectiveness of the murine genomic modification at the OCLN locus to be
successfully converted in the production of a humanized transcript.
A
Fig 28 – RT-PCR analysis of OCLN transcripts. Panel A: The structure of wild type and
recombinant OCLN transcripts is schematically shown. Pink bars represent murine exons,
green bar represents the inserted human CDS, red bar represents SV40 polyadenylation
signal. PCR was performed using a sense primer annealing on the murine sequence shared by
both wild type and recombinant transcripts (pink rightwards arrows) and two different anti-
sense primers: one annealing only on the wild type transcript (pink leftwards arrow), the
other annealing only on the human sequence (green leftwards arrow). Panel B:  PCR results
on liver cDNA were reported. Liver was dissected from wt mice (m/m) and from OCLN
heterozygous mice (m/h). RNA control samples, in which no retrotranscriptase was added (-
RT), were also included (lanes 2, 4, 6, 8).  Amplification using the sense primer paired with the
antisense primer annealing only on the human sequence produced the specific 2.1 kb
fragment for m/h and no one for m/m (lanes 1, 3), while the reaction with the antisense
primer annealing only on the wild type transcript produced the specific 2.4 kb fragment for
both m/h and m/m (lanes 5, 7). No product was observable in –RT controls.
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Fig 29 – Sequence analysis of OCLN RT-PCR products. Liver cDNA from heterozygous OCLN
m/h mouse was specifically amplified to discriminate humanized transcript from the wild type
one. Two different PCR products were obtained and they were further mixed and sequenced.
Only a small region of whole sequence is reported: yellow arrows indicate double picks
corresponding to the nucleotide substitutions between human and murine sequences. These
results demonstrated the liver expression of both wild type and humanized OCLN transcripts
in the heterozygous mouse.
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4.7 Homozygous OCLN h/h mice are not viable
Heterozygous OCLN m/h mice were viable, with normal growth and
exhibited no overt gross phenotypes. To generate homozygous mice, we set
several crosses among our heterozygous, as described in Table 1. 291 mice
were produced from the different mates. Genotype analysis revealed that about
75% were heterozygous OCLN murine / OCLN human (OCLN m/h) and the
others wild type OCLN murine / OCLN murine (OCLN m/m) (Tab 5). These
data indicate that homozygous insertion of human OCLN gene may lead to
prenatal lethality.
Tab 5 – Humanized OCLN knock-in mice genotypes. In this table is shown the OCLN
genotypes of the litters from heterozygous interbreeds, for each of the three OCLN knock-in
lines: neomycin cassette including line, neoOCLN m/h, and lines with neomycin cassette
removed in vivo, OCLN m/h, and in vitro, OCLN-2 m/h. These data are statistically significant
(χ2 < 0.005).
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4.8 Embryonic lethality for homozygous OCLN h/h knock-in mice
The humanized occludin knock-in mouse that we generated did not
show any evident phenotype when carried heterozygous genomic modification.
In contrast, when heterozygous mice were interbred no homozygous
humanized occludin mouse (OCLN h/h) was produced. The genotype analysis
of heterozygous interbreed derived offspring showed Mendelian 1:2 ratio
between wild type homozygous (OCLN m/m) and heterozygous (OCLN m/h)
littermates (Tab 5). This observation indicated that homozygous OCLN h/h
condition was lethal during mouse embryonic life. The same results were
observed for all the three humanized occludin knock-in lines, demonstrating
that this consequence did not correlate either with the presence of neomycin
resistance gene or with FLPe recombination events.
To verify murine embryonic lethality for homozygous humanization of
occludin locus, we collected thirty embryos at 10.5 dpc (days of gestation)
from heterozygous interbreed and analyzed their genotype. Either at this stage
no homozygous OCLN h/h was found (Tab 6).
Tab 6 – Humanized occludin knock-in embryos genotypes. 10.5 dpc embryos were collected
from heterozygous neoOCLN m/h interbreed and they were genotyped. No homozygous
OCLN h/h embryos were found at this embryonic stage (χ2 < 0.005).
Therefore we investigated the genotype in early embryonic stages,
collecting preimplantation embryos from superovulated female heterozygous
mice crossbred with male heterozygous mice. To determine preimplantation
embryos genotype we performed nested PCRs on whole embryos (Fig 30). The
genotype analysis showed the production of homozygous OCLN h/h at 2-cell
(1-2.5 dpc) and morula stages (1-3.5 dpc), whereas no homozygous was found
at blastocyst stage (2-5 dpc) (Tab 7). These results indicate that the genomic
modification introduced in the mouse to humanize occludin gene become lethal
in homozygosity; in particular the mortality appears during embryonic
development from morula to blastocyst stages.
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Fig 30 – Humanized occludin knock-in preimplantation embryos PCR genotyping. Nested
PCRs were performed on whole preimplantation embryos to amplify a wild type allele
product (603 bps) and a recombinant allele product (733 bps). The nested primers are the
same used to genotype mice and are indicated in figure 27A. PCR results are shown for all the
three genotypes: wild type m/m, heterozygous m/h, and homozygous h/h.
Tab 7 – Humanized occludin knock-in preimplantation embryos genotypes. Preimplantation
embryos were collected from superovulated heterozygous OCLN h/m mice interbred with
heterozygous OCLN h/m mice, and they were genotyped. Homozygous OCLN h/h embryos
were found with Mendelian rate at 2-cell and morula stages, whereas no homozygous
blastocyst was produced (χ2 < 0.005).
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Since OCLN null mice have several defects (Saitou et al. 2000), we
wondered whether the embryo lethality of our homozygous OCLN h/h could
be due to an insufficient expression of human gene.  We adopted a real time
PCR approach to measure relative expression levels of both humanized and
wild type occludin genes in the heterozygous mice, according to Pfaffl model
(Pfaffl 2001). Therefore we designed two different oligonucleotide primer pairs
annealing on the 3’ UTR regions, which represent the least conserved sequence
between the two genes, to specifically amplify a wild type allele derived
product and the humanized allele derived one. The real time PCR results were
calculated regarding amplification efficiency of each primer pairs, and they
were normalized for GAPDH reference gene. We analyzed the relative
expression levels of human and murine occludin in liver samples extracted
from wild type and heterozygous OCLN m/h mice (Figg 31-32). The study was
conducted on six animals for each genotype, homogeneous for sex and age:
wild type OCLN m/m, neoOCLN m/h, OCLN m/h, OCLN-2 m/h. The results
indicated a high variability in the expression levels of occludin between
animals with the same genotype. However most of the times the levels of
human OCLN were comparable to those of the murine transcript in each single
heterozygous mouse.
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Fig 31 – Determination of OCLN mRNA levels by real time PCR.
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Fig 31 – Determination of OCLN mRNA levels by real time PCR. Real time PCR results,
normalized for GAPDH, are represented as relative expression of human occludin (green bars)
than murine one (pink bars). For each knock-in genotype (A, NeoR cassette including line; B
and C, lines with NeoR cassette removed, in vivo and in vitro respectively) six animals were
analyzed. A high variability in the expression levels of occludin was observed between animals
with the same genotype. In 13/18 analyzed heterozygous mice the expression level of human
OCLN was comparable than the expression level of murine OCLN.
Fig 32 – Determination of OCLN mRNA levels by real time PCR (Absolute values). Real time
PCR results, normalized for GAPDH, were reported for murine gene (pink points) and for
human gene (green points) in a dispersion graph to compare their levels between wild type
and heterozygous m/h mice of every three OCLN murine lines (wt, N=6; m/h, N=18). No
statistically significant variation was observed between distributions.
To analyze the protein expression of OCLN in humanized mice we
performed a Western blotting using a polyclonal antibody against the C-
terminal 150 amino acid region of human OCLN (Fig 33). This antibody reacts
specifically with mammalian OCLN, including human and mouse proteins.
Indeed it was not possible to discriminate the endogenous protein from the
human one in knock-in mice. However we analyzed the expression of OCLN
protein in heterozygous m/h mice of each OCLN lines (neoOCLN, OCLN,
OCLN-2) to verify possible difference with its expression in wild type mice.
Liver was dissected from wild type and heterozygous OCLN m/h mice and
total proteins extracts were generated using a lysis protocol preserving
transmembrane proteins integrity. A specific band of approximately 60 kDa
was detected in every sample, according to the expected molecular weight of
OCLN (Furuse M et al. 1993). No quantitative difference was observed
between heterozygous and wild type mice. These data indicated that
humanized OCLN heterozygous mice did not express lower levels of liver
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OCLN protein and no different molecular weight protein was generated in
liver.
Fig 33 – OCLN Western blot analysis in OCLN knock-in mice. OCLN protein expression was
analyzed in humanized mice by Western blotting. Liver extracts were generated from
heterozygous OCLN m/h mice containing the NeoR cassette (lanes 1, 2), or with NeoR cassette
removed in vivo (lanes 3, 4) and in vitro (lanes 5, 6), and from wild type OCLN m/m mice
(lanes 7, 8). Polyclonal anti-OCLN antibody detected a specific band of ~60 kDa for every
sample; actin normalization was also performed and no expression levels difference was
observed between heterozygous and wild type mice.
4.9 HCV receptors humanized mice as potential model of virus entry and
infection
The natural species tropism of HCV is limited to humans and
chimpanzees. Indeed the inoculation of HCV-infected sera or of tissue-culture-
derived virus into the mouse does not result in detectable infection (Ploss and
Rice, unpublished data). This resistance phenotype is probably multifactorial,
but is at least partly attributable to a block in HCV entry. The identification of
HCV entry essential factors provides the bases to develop an inbred mouse
model for HCV. Genetic humanization of a mouse strain for species-specific
HCV receptors could overcome the block in entry and could be a useful tool
for analyzing HCV infection in vivo.
Using knock-in approach, we produced novel inbred humanized mouse
strains for three essential HCV receptors, CD81, SR-BI and OCLN. We
adopted a gene targeting strategy to insert human genes in the murine genome,
to achieve native expression patterns of the human HCV entry factor
orthologues. Heterozygous humanized mice are now available for all three
HCV receptors and we are waiting for homozygous generation for CD81 and
SR-BI; unfortunately humanized OCLN mice showed embryonic lethality for
homozygous condition. Humanized mice for single receptors are interbred to
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generate mouse strains expressing different combination of human HCV entry
factors.
Novel potential interactions between our humanized mice and HCV
will be studied. First of all we want to verify the virus entry into the cell of
humanized mouse models. Therefore we are optimizing a protocol to isolate
and culture primary hepatocytes from the mouse, and we are producing HCV
pseudotype particles to perform infectivity assays on the primary hepatocytes.
Murine primary hepatocytes were successfully isolated from CD1 and
C57BL/6 mice liver, using a modified Seglen’s protocol (Seglen 1976, Gandin
et al. 2008). Four-month-old mice were anaesthetized and liver was perfused in
situ through the portal vein with digestion solution containing a collagenase.
After digestion, liver was homogenized and filtered; to isolate only the viable
cells, hepatocytes were passed through a Percoll cushion. Viable isolated
hepatocytes were then seeded in gelatin coated plates and incubated at 5%
CO2, 37°C (Fig 34). To confirm the cellular type specificity of isolated cells
we performed RT-PCR analysis to detect hepatic markers. Total RNA was
extracted from primary cultured cells and from a frozen liver section as control.
RT-PCR for two hepatic markers, albumin and alpha-fetoprotein, was
performed and specific products were amplified for both primary cells and
liver section samples, indicating the hepatic derivation of isolated cells (Fig
35).
Fig 34 – Primary hepatocytes isolated from mouse liver. CD1 wild type mouse liver was in
vivo perfused with collagenase digestion solution and manually homogenized. Primary
hepatocytes were filtered through 70 μm strainer and passed on 37.5% Percoll cushion. 24
hours primary hepatocytes cultured on gelatin coated plates are shown.
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Fig 35 – RT-PCR analysis of isolated murine primary hepatocytes. To verify the cellular type
origin of mouse liver isolated cells RT-PCR was performed to detect hepatic markers, albumin
(ALB) and alpha-fetoprotein (AFP). Total RNA was extracted from 48 hours cultured primary
cells and from liver section and it was retro-transcribed and used as PCR template. ALB and
AFP specific primer pairs amplified respectively a 123 bps region on the albumin transcript
and a 137 bps region on the alpha-fetoprotein transcript. RT-PCR amplified the specific
products for both genes in primary hepatocytes sample (lanes 1, 3) and in liver section control
sample (lanes 5, 7). No product was observable in RNA control samples, in which no
retrotranscriptase was added (lanes 2, 4, 6, 8).
Luciferase infectivity assays were optimized to test virus entry into human and
murine immortalized cell lines and into murine primary hepatocytes. To test
HCV entry HIV pseudo-particles were produced as described by McKeating
(Journal of Virology 2003;77-7:4070–80). 293T cells were cotransfected with a
plasmid encoding an envelope-defective HIV-1 proviral genome expressing a
luciferase reporter gene (NL4.3.Luc.R-E-) and a plasmid encoding full-length
strain H E1E2 HCV glycoproteins. As control, plasmid encoding vesicular
stomatitis virus glycoprotein (VSV-G) was cotransfected to generate
pseudotype viruses with known entry characteristics. These pseudotype
particles were tested to infect human hepatoma cell line (Hep3B), murine
hepatoma cell line (Hepa1.6) and wild type mouse primary hepatocytes (Fig
36). As expected, HCV pseudotype particles entered in human Hep3B while
murine Hepa1.6 and wild type mouse primary hepatocytes were resistant to the
virus entry. Murine hepatic cells were instead permissive to VSV-G
pseudoparticles entry.
Isolation and culture of murine primary hepatocytes and HCV
pseudotype particles infection assay were successfully optimized, and we will
use these model systems to study HCV entry into humanized mice cells.
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Fig 36 – HIV pseudo-particles infectivity. Panel A: HIV pseudotypes bearing strain H native
E1E2 HCV glycoproteins (blue bars) were tested for their ability to infect human Hep3B,
murine Hepa1.6 and wild type murine primary hepatocytes. No virus particle inoculation was
performed for each line as control (red bars). All infections were performed in triplicate, on
120 x 103 cells, and the mean luciferase activity (RLU) is shown. Human Hep3B resulted
permissive to HCV pseudotypes entry, while murine Hepa1.6 and wild type primary
hepatocytes were resistant to particles entry. Panel B: VSV-G pseudotype particles were used
to infect wild type murine primary hepatocytes (green bars); the infection was performed in
triplicate, on 60, 80 and 120 x 103 cells, and luciferase activity ever resulted significantly
higher than no virus particle controls (red bars).
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5. CONCLUSIONS
Investigation of HCV replication and pathogenesis, such as
development of HCV-specific antivirals and vaccines, has been hampered by
the lack of small animal models of HCV infection and propagation.
In the last few years, genetic engineering advances have increased the
ability to modify mouse genome and create inbred mouse models for studying
biological processes in vivo.
In our study we designed a gene targeting strategy to produce novel
humanized mouse strains expressing human-specific HCV entry receptors.
Early results of receptor-mediated HCV entry suggested a critical role for
human CD81 and SR-BI (Pileri et al. 1998, Dubuisson et al. 2003). Recent
studies have identified human occludin as another HCV entry receptor and
provided evidence that CD81 and occludin are the human factor essential to
overcome the cross-species barrier at the level of entry (Ploss et al. 2009).
Therefore, we generated three new knock-in mouse strains respectively for
human CD81, SR-BI and occludin, as in vivo model systems to analyze HCV
entry. We introduced the human genes for these receptors in the mouse genome
by homologous recombination in ES cells. The human coding sequence of
HCV receptors was specifically inserted in murine orthologues loci to achieve
their native expression patterns. These modifications were successfully established in
the genome of murine ES cells, which were used to generate inbred genetically
modified mice. So, we produced humanized knock-in mouse strains for all three
HCV receptors. Molecular analyses of genomic DNA extracted from mice tail
biopsies confirmed the presence and germ line propagation of the human
genes. Then, the effective expression of the inserted human genes was
demonstrated at the transcription level analyzing messenger RNA extracted
from different mice tissues including liver.
Until now, we produced heterozygous humanized mice for all three
HCV receptors, and their inter-crosses will generate homozygous humanized
mice for CD81 and SR-BI. Instead we reported prenatal lethality for
homozygous humanized occludin mice. We demonstrated that homozygous
condition for occludin locus humanization lead to mouse mortality in the early
embryonic development, between morula and blastocyst stages. Since occludin
null mice, though viable, have several defects (Saitou et al. 2000), we asked
whether the observed embryo lethality could be due to a not sufficient
expression of human gene. We performed quantitative analysis of occludin
transcripts in heterozygous mice and we demonstrated that the expression level
of human occludin was comparable than the expression level of murine
occludin. We also analyzed occludin protein expression and demonstrated that
humanized occludin heterozygous than wild type mice did not express lower
levels of liver occludin protein and no different molecular weight protein was
generated in liver. A critical role of occludin in preimplantation mouse embryo
development was reported (Kim et al. 2004). Furthermore, mouse blastocyst
formation was regulated by post-translational control of occludin (Sheth et al.
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2000). Occludin amino acidic substitutions introduced to humanize the mouse
could compromise interactions with its partners, such as ZO-1, and post-
translational modifications of the protein, such as phosphorylation and
glycosylation. These putative molecular alterations could impair the blastocyst
development and explain embryo lethality observed in our homozygous
occludin humanized mice. Further experiments have to be performed to
correlate human occludin homozygous expression to the observed mortality,
and to verify the molecular causes of this phenotype.
To study HCV entry into our humanized mice cells, we successfully
optimized isolation and culture of murine primary hepatocytes and HCV
pseudotype particles infection assay. We will perform this assay on primary
hepatocytes isolated from heterozygous and homozygous mice expressing
different combination of human entry factors. The heterozygous expression of
human receptors could be sufficient to mediate HCV entry into the hepatocyte.
However we could generate homozygous mice for both human CD81 and SR-
BI, whereas only heterozygous humanized occludin mice are available.
Although CD81 and occludin represent the minimal human specific
entry factors while murine SR-BI can mediate HCV entry in cell culture model
systems, we included human SR-BI in our in vivo model since it has been
demonstrated that HCV pseudoparticles entry in NIH3T3 murine cell line co-
transfected with human entry receptors was enhanced by the overexpression of
human SR-BI in the context of the other human proteins (Ploss et al. 2009).
Furthermore, as HCV circulates in the serum associated to lipoproteins and SR-
BI interacts with lipoproteins, this receptor could have in vivo human-specific
entry properties undetermined by the in vitro studies.
Our humanized mice could be an interesting tool for analyzing HCV
infection in vivo. HCV pseudotypes infection assay will demonstrate if the
specific expression of chosen human receptors in knock-in mouse renders its
cells permissive to HCV entry. These next results will provide the evidences to
define our humanized mice as a new inbred model for the in vivo study of
HCV-host interactions.
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